HAEMATO AG: IFRS results Q1 2017

Schönefeld (pta021/26.05.2017/17:45 UTC+2) IFRS results Q1 2017, Sales Eur67.9m, EBIT (operating result) Eur2.8m (prior year period: Eur3.5m)

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved in Q1 2017 an IFRS group turnover of Eur67.9m (previous year period: Eur67.9m) and an operating result (EBIT) of Eur2.8m (previous year period: Eur3.5m).

About HAEMATO:
HAEMATO AG, which was founded in 1993, is a pharmaceutical company. The focus of the operational activities is on the growth markets of patent-free and patent-protected pharmaceuticals. Focal points are therapies of cancer, HIV, and other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the HAEMATO AG share:
Subscribed capital: Eur20,778,898
Listed class of share: Bearer shares

(end)

Emitter:	HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany
Contact Person:	Dr. Christian Pahl
Phone:	+49 30 8973086-70
E-Mail:	ir@haemato.de
Website:	www.haemato-ag.de
ISIN(s):	DE0006190705 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate